{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:37Z","timestamp":1789549357961,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGY23H200007"],"award-info":[{"award-number":["LTGY23H200007"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10067-026-08323-4","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:31:30Z","timestamp":1786559490000},"page":"6051-6060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with discontinuation of bDMARDs and JAK inhibitors in patients with rheumatoid arthritis: a retrospective study"],"prefix":"10.1007","volume":"45","author":[{"given":"Jing","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-1848","authenticated-orcid":false,"given":"Juping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"8323_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2024.102019","volume":"39","author":"C Cubberley","year":"2025","unstructured":"Cubberley C, Maharaj A (2025) Global RA treatment recommendations: an update from the various international societies. Best Pract Res Clin Rheumatol 39:102019. https:\/\/doi.org\/10.1016\/j.berh.2024.102019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8323_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17534259251324820","volume":"31","author":"M Riaz","year":"2025","unstructured":"Riaz M, Rasool G, Yousaf R, Fatima H, Munir N, Ejaz H (2025) Anti-rheumatic potential of biological DMARDs and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis. Innate Immun 31:17534259251324820. https:\/\/doi.org\/10.1177\/17534259251324820","journal-title":"Innate Immun"},{"key":"8323_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063198","volume":"13","author":"M Movahedi","year":"2023","unstructured":"Movahedi M, Choquette D, Coupal L, Cesta A, Li X, Keystone EC et al (2023) Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. BMJ Open 13:e063198. https:\/\/doi.org\/10.1136\/bmjopen-2022-063198","journal-title":"BMJ Open"},{"key":"8323_CR4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, Bergstra SA, Choquette D, Codreanu C et al (2022) Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration. Ann Rheum Dis 81:1358\u20131366. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222586","journal-title":"Ann Rheum Dis"},{"key":"8323_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z, Buch MH, Charles-Schoeman C, Galloway J, Karpouzas GA, Kristensen LE et al (2024) Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol 20:101\u2013115. https:\/\/doi.org\/10.1038\/s41584-023-01062-9","journal-title":"Nat Rev Rheumatol"},{"key":"8323_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267749","volume":"14","author":"S Yoshida","year":"2023","unstructured":"Yoshida S, Miyata M, Suzuki E, Kanno T, Sumichika Y, Saito K et al (2023) Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study. Front Immunol 14:1267749. https:\/\/doi.org\/10.3389\/fimmu.2023.1267749","journal-title":"Front Immunol"},{"key":"8323_CR7","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3899\/jrheum.100050","volume":"37","author":"DL Mattey","year":"2010","unstructured":"Mattey DL, Dawes PT, Hassell AB, Brownfield A, Packham JC (2010) Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. J Rheumatol 37:2021\u20132024. https:\/\/doi.org\/10.3899\/jrheum.100050","journal-title":"J Rheumatol"},{"key":"8323_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1461396","volume":"11","author":"C Plasencia-Rodr\u00edguez","year":"2024","unstructured":"Plasencia-Rodr\u00edguez C, Mart\u00ednez-Feito A, Novella-Navarro M, P\u00e9rez De Diego R, Bonilla G, Gehin JE et al (2024) Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients. Front Med 11:1461396. https:\/\/doi.org\/10.3389\/fmed.2024.1461396","journal-title":"Front Med"},{"key":"8323_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003975","volume":"10","author":"C L\u00f3pez-Medina","year":"2024","unstructured":"L\u00f3pez-Medina C, Calvo-Guti\u00e9rrez J, \u00c1balos-Aguilera MC, Cepas F, Plasencia-Rodr\u00edguez C, Mart\u00ednez-Feito A et al (2024) Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open 10:e003975. https:\/\/doi.org\/10.1136\/rmdopen-2023-003975","journal-title":"RMD Open"},{"key":"8323_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.628548","volume":"12","author":"K-J Li","year":"2021","unstructured":"Li K-J, Chang C-L, Hsin C-Y, Tang C-H (2021) Switching and discontinuation pattern of biologic disease-modifying antirheumatic drugs and tofacitinib for patients with rheumatoid arthritis in Taiwan. Front Pharmacol 12:628548. https:\/\/doi.org\/10.3389\/fphar.2021.628548","journal-title":"Front Pharmacol"},{"key":"8323_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1684-0","volume":"18","author":"T Wilke","year":"2017","unstructured":"Wilke T, Mueller S, Lee SC, Majer I, Heisen M (2017) Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. BMC Musculoskelet Disord 18:332. https:\/\/doi.org\/10.1186\/s12891-017-1684-0","journal-title":"BMC Musculoskelet Disord"},{"key":"8323_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24027-6","volume":"12","author":"HK Min","year":"2022","unstructured":"Min HK, Kim SH, Lee S-H, Kim H-R (2022) Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis. Sci Rep 12:19951. https:\/\/doi.org\/10.1038\/s41598-022-24027-6","journal-title":"Sci Rep"},{"key":"8323_CR13","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","volume":"41","author":"Y Khader","year":"2022","unstructured":"Khader Y, Beran A, Ghazaleh S, Lee-Smith W, Altorok N (2022) Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol 41:3615\u20133627. https:\/\/doi.org\/10.1007\/s10067-022-06307-8","journal-title":"Clin Rheumatol"},{"key":"8323_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.31138\/mjr.090723.pof","volume":"35","author":"S Boussaid","year":"2024","unstructured":"Boussaid S, Tbini H, Rekik S, Khaled S, Rahmouni S, Zouaoui K et al (2024) Predictors of drug retention and survival rate of bDMARDs in rheumatoid arthritis: a four-year real-life Tunisian experience. Mediterr J Rheumatol 35:448. https:\/\/doi.org\/10.31138\/mjr.090723.pof","journal-title":"Mediterr J Rheumatol"},{"key":"8323_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/rheumatology\/keae103","volume":"64","author":"CJT van der Togt","year":"2025","unstructured":"van der Togt CJT, den Broeder N, Boonstra MS, van der Maas A, den Broeder AA, van Herwaarden N (2025) Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study. Rheumatology (Oxford) 64:533\u2013540. https:\/\/doi.org\/10.1093\/rheumatology\/keae103","journal-title":"Rheumatology (Oxford)"},{"key":"8323_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02233-9","volume":"22","author":"A Kawabe","year":"2020","unstructured":"Kawabe A, Nakano K, Kubo S, Asakawa T, Tanaka Y (2020) Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Res Ther 22:136. https:\/\/doi.org\/10.1186\/s13075-020-02233-9","journal-title":"Arthritis Res Ther"},{"key":"8323_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/03009742.2025.2471713","volume":"54","author":"K Lauridsen","year":"2025","unstructured":"Lauridsen K, Duch K, Mortensen A, Cordtz R, Kristensen S, Hetland ML et al (2025) Sex differences in treatment response in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitor: a cohort study from the DANBIO registry. Scand J Rheumatol 54:252\u2013262. https:\/\/doi.org\/10.1080\/03009742.2025.2471713","journal-title":"Scand J Rheumatol"},{"key":"8323_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15052075","volume":"15","author":"N Hao","year":"2026","unstructured":"Hao N, Kondo N, Arai K, Kudo N, Murai T, Fujisawa J et al (2026) Five-year drug survival and discontinuation reasons for eight biological disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective analysis of 1182 patients from the Niigata Orthopedic Surgery Rheumatoid Arthritis Database (NOSRAD). J Clin Med 15:2075. https:\/\/doi.org\/10.3390\/jcm15052075","journal-title":"J Clin Med"},{"key":"8323_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Thein D, L\u00f8rup EH, Nielsen M-L, Nymand L et al (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 53:151979. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979","journal-title":"Semin Arthritis Rheum"},{"key":"8323_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/msc.1928","volume":"22","author":"H Jeries","year":"2024","unstructured":"Jeries H, Daood R, Hijazi B, Golan-Cohen A, Green I, Merzon E et al (2024) Drug survival on first biologic therapy among late-onset rheumatoid arthritis patients compared to early-onset patients: a population-based cohort study. Musculoskelet Care 22:e1928. https:\/\/doi.org\/10.1002\/msc.1928","journal-title":"Musculoskelet Care"},{"key":"8323_CR21","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen TS, Turesson C, Kapetanovic M, Englund M, Turkiewicz A, Christensen R et al (2017) EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: a prospective observational study of patients registered in the south Swedish SSATG registry. PLoS ONE 12:e0169946. https:\/\/doi.org\/10.1371\/journal.pone.0169946. (Kuwana M, editor)","DOI":"10.1371\/journal.pone.0169946"},{"key":"8323_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/ard-2023-224670","volume":"83","author":"R Aymon","year":"2024","unstructured":"Aymon R, Mongin D, Bergstra SA, Choquette D, Codreanu C, De Cock D et al (2024) Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study). Ann Rheum Dis 83:421\u2013428. https:\/\/doi.org\/10.1136\/ard-2023-224670","journal-title":"Ann Rheum Dis"},{"key":"8323_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00296-021-04989-y","volume":"41","author":"ME Naffaa","year":"2021","unstructured":"Naffaa ME, Hassan F, Golan-Cohen A, Merzon E, Green I, Saab A et al (2021) Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study. Rheumatol Int 41:1905\u20131913. https:\/\/doi.org\/10.1007\/s00296-021-04989-y","journal-title":"Rheumatol Int"},{"key":"8323_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14740338.2023.2172157","volume":"22","author":"K Velthuis","year":"2023","unstructured":"Velthuis K, Jessurun NT, Nguyen TDM, Scholl J, Jansen JRG, van Lint JA et al (2023) First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept. Expert Opin Drug Saf 22:485\u2013492. https:\/\/doi.org\/10.1080\/14740338.2023.2172157","journal-title":"Expert Opin Drug Saf"},{"key":"8323_CR25","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1007\/s12325-023-02607-w","volume":"40","author":"V Rosenberg","year":"2023","unstructured":"Rosenberg V, Chodick G, Xue Z, Faccin F, Amital H (2023) Real-world data of adherence and drug survival of biologics in treatment-na\u00efve and treatment-experienced adult patients with rheumatoid arthritis. Adv Ther 40:4504\u20134522. https:\/\/doi.org\/10.1007\/s12325-023-02607-w","journal-title":"Adv Ther"},{"key":"8323_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250877","volume":"16","author":"C-T Lin","year":"2021","unstructured":"Lin C-T, Huang W-N, Tsai W-C, Chen J-P, Hung W-T, Hsieh T-Y et al (2021) Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: analysis from the TRA Clinical Electronic Registry. PLoS ONE 16:e0250877. https:\/\/doi.org\/10.1371\/journal.pone.0250877. (Rai VK, editor)","journal-title":"PLoS ONE"},{"key":"8323_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00296-025-05859-7","volume":"45","author":"LM Risser","year":"2025","unstructured":"Risser LM, Witte T, Englbrecht M, Strunz P-P, Froehlich M, Schmalzing M et al (2025) Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis \u2013 a retrospective analysis from the RHADAR database. Rheumatol Int 45:100. https:\/\/doi.org\/10.1007\/s00296-025-05859-7","journal-title":"Rheumatol Int"},{"key":"8323_CR28","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1007\/s10067-024-07161-6","volume":"43","author":"P-C Shih","year":"2024","unstructured":"Shih P-C, Hung P-C, Leong P-Y, Hsu J-N, Yang C-C, Wei JCC et al (2024) Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: a population-based cohort study. Clin Rheumatol 43:3625\u20133637. https:\/\/doi.org\/10.1007\/s10067-024-07161-6","journal-title":"Clin Rheumatol"},{"key":"8323_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154273","volume":"241","author":"V Ricci","year":"2023","unstructured":"Ricci V, Ricci C, Tamborrini G, Chang K-V, Mezian K, Zunica F et al (2023) From histology to sonography in synovitis: EURO-MUSCULUS\/USPRM approach. Pathol - Res Pract 241:154273. https:\/\/doi.org\/10.1016\/j.prp.2022.154273","journal-title":"Pathol - Res Pract"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08323-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08323-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:04:56Z","timestamp":1789545896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08323-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8323"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08323-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by the ethics committee of the Taizhou Hospital of Zhejiang Province.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}